11.68
+0.29(+2.55%)
Currency In USD
| Previous Close | 11.39 |
| Open | 11.39 |
| Day High | 11.73 |
| Day Low | 11.34 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 125,958 |
| Average Volume | 934,672 |
| Market Cap | 890.43M |
| PE | -4.19 |
| EPS | -2.79 |
| Moving Average 50 Days | 11.04 |
| Moving Average 200 Days | 17.39 |
| Change | 0.29 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $599.16 as of July 01, 2025 at a share price of $11.39. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $855.11 as of July 01, 2025 at a share price of $11.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforce
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire Inc.
Jun 06, 2025 11:00 AM GMT
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announ
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing t